• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Improving the nutritional situation of patients with advanced non-small cell lung cancer (NSCLC) through off-label medication].

作者信息

Schepers-von Ohlen Daphne

机构信息

Klinik für Strahlentherapie, UKSH, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Deutschland.

Arbeitsgruppe junge DEGRO der Deutschen Gesellschaft für Radioonkologie e. V. (DEGRO), Berlin, Deutschland.

出版信息

Strahlenther Onkol. 2024 Nov;200(11):997-999. doi: 10.1007/s00066-024-02299-3. Epub 2024 Sep 5.

DOI:10.1007/s00066-024-02299-3
PMID:39235472
Abstract
摘要

相似文献

1
[Improving the nutritional situation of patients with advanced non-small cell lung cancer (NSCLC) through off-label medication].[通过超说明书用药改善晚期非小细胞肺癌（NSCLC）患者的营养状况]
Strahlenther Onkol. 2024 Nov;200(11):997-999. doi: 10.1007/s00066-024-02299-3. Epub 2024 Sep 5.
2
[Correction: Improving the nutritional situation of patients with advanced non-small cell lung cancer (NSCLC) through off-label medication].[更正：通过超说明书用药改善晚期非小细胞肺癌（NSCLC）患者的营养状况]
Strahlenther Onkol. 2024 Dec;200(12):1103-1104. doi: 10.1007/s00066-024-02314-7.
3
The relationship between nutritional status and prognosis in patients with locally advanced and advanced stage lung cancer.营养状况与局部晚期和晚期肺癌患者预后的关系。
Support Care Cancer. 2021 Jun;29(6):3357-3365. doi: 10.1007/s00520-020-05856-5. Epub 2020 Oct 30.
4
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.多中心、随机、开放标签、平行分组、临床二期研究，评估免疫营养在改善接受系统营养咨询的转移性非小细胞肺癌患者免疫治疗疗效中的作用。
BMC Cancer. 2022 Nov 24;22(1):1212. doi: 10.1186/s12885-022-10296-x.
5
The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.预后营养指数（PNI）和中性粒细胞与淋巴细胞比值（NLR）对铂类化疗治疗晚期非小细胞肺癌的预后价值。
Ann Palliat Med. 2020 May;9(3):967-978. doi: 10.21037/apm.2020.04.31. Epub 2020 Apr 21.
6
[A Prognostic Model of Elderly Patients with Non-small Cell Lung Cancer 
Based on Geriatric Nutritional Risk Index].基于老年营养风险指数的老年非小细胞肺癌患者预后模型
Zhongguo Fei Ai Za Zhi. 2023 Jul 20;26(7):497-506. doi: 10.3779/j.issn.1009-3419.2023.106.14.
7
[Clinical application value of prognostic nutritional index for predicting survival in patients with advanced non-small cell lung cancer].[预后营养指数对预测晚期非小细胞肺癌患者生存的临床应用价值]
Zhonghua Zhong Liu Za Zhi. 2017 Feb 23;39(2):146-149. doi: 10.3760/cma.j.issn.0253-3766.2017.02.015.
8
Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.联合全身免疫炎症指数和预后营养指数可预测接受铂类双联化疗的晚期非小细胞肺癌患者的预后。
Front Oncol. 2023 Apr 3;13:996312. doi: 10.3389/fonc.2023.996312. eCollection 2023.
9
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.AK112，一种新型的PD-1/血管内皮生长因子双特异性抗体，联合化疗用于晚期非小细胞肺癌（NSCLC）患者：一项开放标签、多中心、II期试验。
EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug.
10
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.阿维鲁单抗联合阿昔替尼治疗既往治疗的非小细胞肺癌或初治、顺铂禁忌的尿路上皮癌的 II 期开放标签试验。
ESMO Open. 2023 Jun;8(3):101173. doi: 10.1016/j.esmoop.2023.101173. Epub 2023 May 2.

本文引用的文献

1
A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.奥氮平治疗癌症恶病质综合征的综述
Pharmacy (Basel). 2024 Feb 17;12(1):34. doi: 10.3390/pharmacy12010034.
2
Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.米氮平作为非小细胞肺癌伴厌食患者的食欲刺激剂：一项随机临床试验。
JAMA Oncol. 2024 Mar 1;10(3):305-314. doi: 10.1001/jamaoncol.2023.5232.
3
Mirtazapine versus Megestrol in the Treatment of Anorexia-Cachexia Syndrome in Patients with Advanced Cancer: A Randomized, Double-Blind, Controlled Phase II Clinical Trial.
米氮平与甲地孕酮治疗晚期癌症患者厌食-恶病质综合征的随机、双盲、对照II期临床试验
Cancers (Basel). 2023 Jul 12;15(14):3588. doi: 10.3390/cancers15143588.
4
Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.癌症恶病质：美国临床肿瘤学会指南快速推荐更新
J Clin Oncol. 2023 Sep 1;41(25):4178-4179. doi: 10.1200/JCO.23.01280. Epub 2023 Jul 12.
5
Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.米氮平治疗癌症相关性厌食和恶病质：一项双盲安慰剂对照随机试验
J Pain Symptom Manage. 2021 Dec;62(6):1207-1215. doi: 10.1016/j.jpainsymman.2021.05.017. Epub 2021 May 26.
6
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.癌症患者的食欲问题：病理生理学、诊断和治疗。
Cancer Treat Res Commun. 2021;27:100336. doi: 10.1016/j.ctarc.2021.100336. Epub 2021 Feb 13.
7
What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review.米氮平治疗癌症相关症状的证据有哪些？系统评价。
Support Care Cancer. 2020 Apr;28(4):1597-1606. doi: 10.1007/s00520-019-05229-7. Epub 2019 Dec 19.
8
FAACT-Anorexia Cachexia Scale: Cutoff Value for Anorexia Diagnosis in Advanced Non-Small Cell Lung Cancer Patients.FAACT-厌食恶病质量表：晚期非小细胞肺癌患者厌食症诊断的临界点。
Nutr Cancer. 2019;71(3):409-417. doi: 10.1080/01635581.2018.1506488. Epub 2018 Oct 1.
9
Effect of Mirtazapine on Gastric Emptying in Patients with Cancer-associated Anorexia.米氮平对癌症相关性厌食症患者胃排空的影响。
Indian J Palliat Care. 2017 Jul-Sep;23(3):335-337. doi: 10.4103/IJPC.IJPC_17_17.